Dernière mise à jour :
26/03/2024
Anticancéreux   Fluorouracil  
Injectable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Acoflut Mexique
Adrucil Etats Unis d’Amérique
Eurofluor Allemagne
Fivocil Inde
Fivoflu Inde, Mexique
Fluorouracil Afrique du sud, Autriche, Belgique, Brésil, Canada, Danemark, Espagne, Etats Unis d’Amérique, Finlande, Grande Bretagne, Grèce, Hongrie, Italie, Norvège, Pays bas, Pologne, Portugal, Serbie, Suisse, Turquie
Fluorouracile France
Flurablastin Danemark, Finlande, Norvège, Suède
Fluracedyl Belgique, Luxembourg, Malaisie, Pays bas
Fluroblastin Afrique du sud
Fluroblastine Belgique
Flurox Mexique
Neofluor Allemagne
Neoflur Egypte
Oncofu Argentine
Ribofluor Allemagne
Triosules Argentine
Bibliographie   Injectable   Bibliographie : Fluorouracil  
Type Source
3 Revue Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
5 Revue Stiles ML, Allen LV Jr, Prince SJ.
Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes.
Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
33 Revue Baud-Camus F, Crauste-Manciet S, Klein E, Richard L, Brossard D.
Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs.
Am J Health-Syst Pharm 1996 ; 53: 1457-1458.
39 Revue Farhang-Asnafi S, Callaert S, Barre J, Tillement JP, Thebault A.
Influence of intravenous admixtures on the stability of the new solution of 5-fluorouracil.
J Pharm Clin 1997 ; 16: 45-48.
40 Revue Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC.
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Pharm Sci Communications 1994 ; 4: 97-101.
49 Revue Trissel LA, Martinez JF.
Compatibility of granisetron hydrochloride with selected alkaline drugs.
Am J Health-Syst Pharm 1995 ; 52: 208.
57 Revue Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Revue Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Revue Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Revue Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Revue Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Revue Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110 Revue Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM.
Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers.
Int J Pharm 1989 ; 54: 181-189.
138 Revue Corbrion V, Crauste-Manciet S, Allain P, Brossard D.
Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint.
Am J Health-Syst Pharm 1997 ; 54: 1845-1848.
142 Revue Rochard EB, Barthes DMC, Courtois PY.
Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs.
Am J Hosp Pharm 1992 ; 49: 619-623.
153 Revue Wang DP, Chang LC, Lee DK.
Stability of fluorouracil-metoclopramide hydrochloride admixture.
Am J Health-Syst Pharm 1995 ; 52: 98-99.
155 Revue Trissel LA, Martinez JF, Xu QA.
Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium.
Am J Health-Syst Pharm 1995 ; 52: 710-715.
156 Revue Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T.
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Anticancer Drugs 1995 ; 6: 163-164.
163 Revue Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA.
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
J Clin Pharm Ther 1994 ; 19: 127-133.
169 Revue Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Revue Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Revue Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Revue Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Revue Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
411 Revue Woloschuk DMM, Wermeling JR, Pruemer JM.
Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 2158-2160.
413 Revue Stewart CF, Fleming RA.
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
Am J Hosp Pharm 1990 ; 47: 1373-1377.
415 Revue Stiles ML, Allen LV, Tu YH.
Stability of fluorouracil administered through four portable infusion pumps.
Am J Hosp Pharm 1989 ; 46: 2036-2040.
431 Revue McRae MP, King JC.
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.
Am J Hosp Pharm 1975 ; 33: 1010-1013.
484 Revue Northcott M, Allsopp MA, Powell H, Sewell GJ.
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions.
J Clin Pharm Ther 1991 ; 16: 123-129.
492 Revue Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
513 Revue Xu QA, Trissel LA, Martinez JF.
Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride.
Ann Pharmacotherapy 1996 ; 30: 756-761.
514 Revue Xu QA, Trissel LA, Martinez JF.
Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers.
Ann Pharmacotherapy 1997 ; 31: 297-302.
763 Revue Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
840 Revue Biondi L, Nairn JG.
Stability of 5-fluorouracil and flucytosine in parenteral solutions.
Can J Hosp Pharm 1986 ; 39: 60-66.
842 Revue Pinguet F, Favre G, Canal P, Pujol A, Soula G.
Stability of 5-fluorouracil to heat and light.
J Pharm Clin 1990 ; 9: 155-158.
844 Revue Rochard E, Chapelle G, Bouquet S, Barthes D, Courtois PH.
Stability of fluorouracil and cytarabine in ethylvinylacetate containers.
J Pharm Clin 1989 ; 9: 31-35.
905 Revue Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Revue Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1040 Revue Quebbeman EJ, Hamid AAR, Hoffman NE, Ausman RK.
Stability of fluorouracil in plastic containers used for continuous infusion at home.
Am J Hosp Pharm 1984 ; 41: 1153-1156.
1228 Revue Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1325 Revue Hardin TC, Clibon U, Page CP, Cruz AB.
Compatibility of 5-fluorouracil and total nutrition solutions.
JPEN 1982 ; 6: 163-165.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Revue Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1475 Revue Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M.
Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs.
J Pharm Biomed Anal 1996 ; 14: 395-399.
1501 Revue Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratoire Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1812 Revue Fuhrman LC, Godwin DA, Davis RA.
Stability of 5-fluorouracil in an extemporaneously compounded ophtalmic solution.
Int J Pharm Compound 2000 ; 4, 4: 320-323.
1817 Revue Roberts S, Sewell GJ.
Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®.
J Oncol Pharm Practice 2003 ; 9: 109-112.
1842 Revue Sadjack A, Wintersteiger R.
Compatibility of morphin, baclofen, floxuridine and fluorouracil in an implantable infusion pump.
Arzneimittel Forschung 1995 ; 45: 93-98.
1925 Revue Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Revue Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Revue Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
1998 Revue Allwood MC.
Fluorouracil precipitate.
Am J Health-Syst Pharm 1998 55: 1315-1316.
2009 Revue Trissel LA, Zhang Y.
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2130 Revue Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J.
Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique.
Bull Cancer 1999 ; 86, 11: 946-954.
2181 Revue Milano G, Renée N.
Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique.
Bull Cancer 1995 ; 82: 189-195.
2262 Revue Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2323 Revue Galanti L, Lebitasy M.P, Hecq J.D, Cadrobbi J, Vanbeckbergen D, Jamart J.
Long-Term Stability of 5-Fluorouracil in 0.9% Sodium Chloride after Freezing, Microwave Thawing, and Refrigeration
Can J Hosp Pharm 2009 ; 62, 1
3369 Laboratoire Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3474 Laboratoire Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3531 Laboratoire Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3574 Laboratoire Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3578 Laboratoire Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3580 Laboratoire Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3634 Laboratoire Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
Accord Healthcare 2011
3637 Laboratoire Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3645 Laboratoire Doxorubicin - Summary of Product Characteristics
Accord Healthcare 2014
3670 Revue Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3873 Revue Tan X, Hu J.
Incompatibility between irinotecan and fluorouracil injections
Am J Health-Syst Pharm 2016 ; 73:755.
3948 Revue Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4568 Revue Closset M,Onorati S, Colsoul M.L,Goderniaux N,Bihin B, Jamart J, Soumoy L, Hecq J.D, Odou P, Galanti L.
Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump.
Journal of Chemotherapy 2021
4735 Revue Closset M, Onorati S, Colsoul M-L, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq J-D, Odou P, Galanti L.
Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags.
J Oncol Pharm Practice 2023 ;29,8:1878 - 1883
4759 Poster Ma NH, Charbonneau LF, Law S, Walker S.
Stability of 5-fluorouracil at 4°C, 25°C, and 33°C stored in NiproSureFuser+ Ambulatory Balloon Infusers.
Sunnybrook Healt Science Centre 2023

  Mentions Légales